v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss $ (2,624,972) $ (1,641,226)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense, net 1,355,017 328,661
Changes in operating assets and liabilities, net    
Other current assets (621,543) (35,857)
In-process research and development accrued expenses (3,000,000) 0
Accounts payable, accrued expenses and other current liabilities (770,968) (311,239)
Operating lease right-of-use assets and liabilities, net (850) 4,238
Net cash used in operating activities (5,663,316) (1,655,423)
Cash flows from investing activities:    
Purchase of short-term investments (1,925,828) (983,307)
Maturities of short-term investments 1,600,000 0
Net cash used in investing activities (325,828) (983,307)
Cash flows from financing activities:    
Cash proceeds from the sales of common stock under a Capital on DemandTM Sales Agreement 0 3,192,619
Proceeds from the exercise of stock options 15,447 0
Taxes paid related to net share settlement of vested restricted stock units (131,129) (10,738)
Net cash (used in) provided by financing activities (115,682) 3,181,881
Effect of exchange rates (54) (1,652)
Net (decrease) increase in cash and cash equivalents (6,104,880) 541,499
Cash and cash equivalents at beginning of period 45,816,289 7,266,080
Cash and cash equivalents at end of period $ 39,711,409 $ 7,807,579